TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00597753
Drug: peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Study: NCT00597753
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Study: NCT01125943
Drug: Nitroprusside
Normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra arterial infusion
Study: NCT01125943
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intra arterial infusion
Study: NCT03439293
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab IV infusion.
Study: NCT03439293
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets.
Study: NCT01703949
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01013649
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01013649
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00332839
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
Study: NCT00332839
Drug: Cyclosporin A (CsA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose was based on the participants' blood level of C0h (80-150 ng/ml).
Study: NCT00332839
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose was based on the participants' blood level of C0h (5-10 ng/ml).
Study: NCT00493181
Drug: Interleukin-11 (IL-11 or Neumega)
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
Study: NCT00803218
Drug: Fluticasone Propionate 0.005% Ointment-Test product
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Small amount applied and evaluated over the course of one day
Study: NCT03013127
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy.
Study: NCT02455141
Drug: Taxanes plus Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
Study: NCT04227769
Drug: Anakinra Prefilled Syringe
Normalized name: anakinra Prefilled Syringe
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
Study: NCT01851278
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose means 40mg or 2ml of triamcinolone hexacetonide
Study: NCT01851278
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose means 20mg or 1 ml of triamcinolone hexacetonide
Study: NCT00246909
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03011814
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03737643
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
Study: NCT03737643
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab by intravenous infusion
Study: NCT00614458
Drug: Raltegravir; valproic acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
Study: NCT03737643
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets
Study: NCT03737643
Drug: Placebo olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo tablets to match olaparib
Study: NCT03737643
Drug: Durvalumab placebo
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo for intravenous infusion
Study: NCT03737643
Drug: Carboplatin+Paclitaxel
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care chemotherapy
Study: NCT04150900
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
Study: NCT04150900
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT03447470
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1
Study: NCT02850445
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
Study: NCT00657397
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone sirup once daily
Study: NCT03363425
Drug: Lidocaine Iv
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine Iv
Study: NCT03363425
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine iv
Study: NCT03063671
Drug: Ketamine, bupivacine,dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: thoracic epidural catheter insertion at T4-5
Study: NCT01606215
Drug: Mesenchymal stem cells
Normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0-2.0 million cells/kg body weight
Study: NCT00959335
Drug: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00959335
Drug: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03180684
Drug: Imiquimod 5% Cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
Study: NCT00957593
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oxytocin once in active labor
Study: NCT00957593
Drug: Oxytocin discontinuation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be stopped once in active labor
Study: NCT00170924
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03380936
Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]
Normalized name: tacrolimus Extended Release Oral Tablet [Envarsus]
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
Study: NCT00558571
Drug: BI 10773 low dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00558571
Drug: BI 10773 medium dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00558571
Drug: BI 10773 high dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04890704
Drug: Curcuminoid
Normalized name: Curcuminoids
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
Study: NCT02721186
Drug: MDA with DHAp and SLD Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00752596
Drug: Azimilide 2HCl
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
Study: NCT04464707
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose A or Dose B subcutaneous
Study: NCT01975831
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study: NCT01975831
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study: NCT00879879
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg losartan taken daily by mouth in capsule form for 1 year
Study: NCT01569464
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)
Study: NCT02178683
Drug: Tacrolimus and MMF.
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
Study: NCT02581839
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Study: NCT02165176
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03539224
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
Study: NCT04352777
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 - 150mg tablet BID as prescribed per standard of care
Study: NCT04352777
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg as prescribed per standard of care
Study: NCT02390219
Drug: Lumacaftor
Normalized name: Lumacaftor
DrugBank: Lumacaftor (DB09280)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02390219
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00204932
Drug: conjugated linoleic acid
Normalized name: CONJUGATED LINOLEIC ACID
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
Study: NCT00667433
Drug: Raltegravir + Truvada
Normalized name: Truvada
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
Study: NCT03539224
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
Study: NCT03024580
Drug: Megestrol Acetate 160Mg Tablet
Normalized name: megestrol acetate 160 MG
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 160 mg PO daily
Study: NCT03024580
Drug: Anastrozole 1Mg Tablet
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 1 mg PO daily OR
Study: NCT03024580
Drug: Letrozole 2.5Mg Tablet
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg PO daily OR
Study: NCT03024580
Drug: Exemestane 25 MG
Normalized name: exemestane 25 MG
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25 mg PO daily
Study: NCT03024580
Drug: Tamoxifen 20Mg Tablet
Normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg PO daily
Study: NCT03024580
Drug: Fulvestrant 50Mg Solution for Injection
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg IM d1, d14, d28 and q28 days
Study: NCT03448081
Drug: Calcipotriene
Normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene ointment (0.005%)
Study: NCT00796354
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Study: NCT00676221
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid
Study: NCT00791232
Drug: extended-release (ER) OROS paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00349310
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01230385
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
Study: NCT01230385
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
Study: NCT01230385
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
Study: NCT01230385
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
Study: NCT01230385
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
Study: NCT01562873
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02581943
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02581943
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00833079
Drug: Tacrolimus 0.1% manufactured by Taro
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study: NCT00833079
Drug: Protopic - Tacrolimus 0.1%
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study: NCT01297569
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03499249
Drug: N-Acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
Study: NCT02601950
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Study: NCT00833079
Drug: Tacrolimus Vehicle manufactured by Taro
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study: NCT03579316
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03579316
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03579316
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00318344
Drug: Atuna Racemosa
Normalized name: Platanus racemosa pollen
DrugBank: Tuna (DB10574)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03945292
Drug: Fazisiran Injection
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution for subcutaneous (sc) injection
Study: NCT01863550
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT01863550
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01863550
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01863550
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04285567
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Study: NCT04285567
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
Study: NCT04285567
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
Study: NCT04285567
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.